Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.
Dana DiRenzo discusses the impact of rheumatic diseases on mental health, and treatments and tools that are available to help support patients with these conditions.
Patients initiating denosumab have a similar 3-year fracture risk to those initiating alendronate, regardless of sex, age, or fracture history, show results of a large study among Danish patients in routine clinical practice.
Increasing levels of high-density lipoprotein cholesterol are associated with a reduction in cardiovascular risk among rheumatoid arthritis patients undergoing treatment with the Janus kinase inhibitor tofacitinib, researchers report.
Dana DiRenzo discusses the impact of rheumatic diseases on mental health, and treatments and tools that are available to help support patients with these conditions.
Findings from a systematic review suggest that long-term drug treatment is associated with a reduction in fracture risk among women with osteoporosis, with different agents having varying long-term safety profiles.
Doubling the dose interval of subcutaneous tocilizumab after 24 weeks reduces the likelihood of maintaining remission without improving tolerability in patients with moderate-to severe rheumatoid arthritis, study findings indicate.
Findings from the TRACE RA trial suggest that atorvastatin has a favorable safety profile and may reduce low-density lipoprotein cholesterol levels in patients with rheumatoid arthritis.
Dafna Gladman speaks to medwireNews about the trial data supporting the use of Janus kinase inhibitors in patients with psoriatic arthritis, and discusses the impact these agents may have.
medwireNews takes a look at the efficacy and safety profiles of JAK inhibitors for the treatment of rheumatoid arthritis, and addresses some common questions about their use.
A panel of four soluble biomarkers comprising markers of cartilage metabolism, metabolic syndrome, and inflammation could distinguish psoriatic arthritis from osteoarthritis, researchers report.
